首页 雷普里根(usRGEN)-基本信息

雷普里根(usRGEN)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:205.35

最高价:207.54

成交量:229293.0

昨收价:206.1

最低价:202.75

最新价:207.02

行情图标
概要信息

中文名称:雷普里根


英文名称:Repligen


行业:医疗


简介:Repligen Corporation是供应生物制药关键产品的领军者


电话:1-781-2500111


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Repligen Corporation是一家生命科学公司,主要从事在生产单株抗体及其他生物制药时使用的生物制剂&耗材产品的开发、制造和销售。 Repligen公司生产各种型式的蛋白质A(Protein A),一种关键试剂,应用在单株抗体分离及纯化的生化程序。 Repligen提供各种生长因子与细胞过滤产品,应用在生化程序中的发酵步骤,来增加细胞生长及生产率,以及提供层析技术产品,应用在生物产品纯化程序。 Repligen生产和销售层析技术产品,包括生物纯化用的OPUS预注管柱、以及专属蛋白质A媒介与质控试剂。 Repligen公司拥有治疗性核心产品,包括治疗弗瑞德瑞克氏失调症基因(FRDA)的组织蛋白去乙醯抑制剂;以及RG1068,是一种已发展成为新型显像剂的合成人体激素,应用在运用核磁共振影像(MRI)来为胰脏炎及其他胰脏疾病患者检测胰腺管异常。 Repligen提供交替切流式系统,一种过滤装置,用来改善生化程序中发酵步骤的产品产率。Repligen Corporation通过直销或经销商方式,销售其产品给全球各种生命科学公司、生物制药生产企业、委外代工服务业(CMO)。Repligen Corporation(RGEN)收购、剥离: 2008年,Repligen剥离某些知识产权给百时美施贵宝(Bristol-Myers Squibb); 2011年,Repligen以2640万美金收购Novozymes(OMX:NZYM B)的生物制品资产; 2016年12月,Repligen(RGEN)将以3900万美元现金收购TangenX Technology。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-14 Snodgres Jon Chief Financial Officer Sell 295 85.95
2019-06-16 Dawes (Karen A) Director Sell 1295 77.35
2019-06-16 Dawes (Karen A) Director Buy 20000 4.96
2019-05-22 Cooper (Glenn L) Director Sell 4734 66.91
2019-05-22 Cooper (Glenn L) Director Buy 24000 5.00
2019-05-22 Cooper (Glenn L) Director Sell 266 67.53
2019-05-14 Ryan (Thomas F Jr) Director Buy 923 --
2019-05-14 Muir (Glenn P) Director Buy 923 --
2019-05-14 Barthelemy (Nicolas M) Director Buy 923 --
2019-05-14 Dawes (Karen A) Director Buy 1292 --
2019-05-14 Cooper (Glenn L) Director Buy 923 --
2019-05-14 Cox (John G) Director Buy 923 --
2019-05-12 Kuriyel (Ralf) Officer Buy 8000 --
2019-05-12 Snodgres Jon Chief Financial Officer Buy 8000 --
2019-03-24 Snodgres Jon Chief Financial Officer Sell 5458 58.45
2019-03-24 Snodgres Jon Chief Financial Officer Sell 1009 59.05
2019-03-17 Hunt (Anthony John) Chief Executive Officer Sell 4009 60.45
2019-03-17 Hunt (Anthony John) Chief Executive Officer Sell 500 60.91
2019-03-17 Hunt (Anthony John) Chief Executive Officer Sell 10041 59.24
2019-03-04 Snodgres Jon Chief Financial Officer Sell 2645 58.52
2019-03-04 Kuriyel (Ralf) Officer Sell 2240 58.53
2019-03-04 Hunt (Anthony John) Chief Executive Officer Sell 13000 58.50
2019-02-28 Kuriyel (Ralf) Officer Buy 4700 --
2019-02-28 Snodgres Jon Chief Financial Officer Buy 4700 --
2019-02-27 Hunt (Anthony John) Chief Executive Officer Buy 22681 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Lord, Abbett & Co LLC 710088 1.48% -23203 -3.16% 2019-03-31
Hartford Funds Management Company, LLC 1547553 3.00% -6567 -0.42% 2019-07-31
Conestoga Capital Advisors, LLC 1637430 3.41% 21393 1.32% 2019-03-31
Fred Alger Management Inc 1643045 3.42% 548054 50.05% 2019-03-31
State Street Corporation 1930767 4.02% -12397 -0.64% 2019-03-31
Wellington Management Company LLP 2212559 4.61% 256717 13.13% 2019-03-31
Vanguard Group Inc 4115290 8.57% 84619 2.10% 2019-03-31
BlackRock Fund Advisors 4695353 9.11% -475748 -9.20% 2019-07-31
BlackRock Inc 5650666 11.77% 66580 1.19% 2019-03-31
Macquarie Group Ltd 1120124 2.33% 54944 5.16% 2019-03-31
Vanguard Investments Australia Ltd 1169999 2.27% 177 0.02% 2019-07-31
OppenheimerFunds Inc 1082943 2.26% 89226 8.98% 2019-03-31
Delaware Management Company 778233 1.51% -95123 -10.89% 2019-07-31
Northern Trust Investments Inc 794436 1.54% 24038 3.12% 2019-07-31
Jackson National Asset Management LLC 821807 1.59% 130831 18.93% 2019-07-31
SSGA Funds Management Inc 904310 1.75% -2176 -0.24% 2019-07-31
Stephens Inv Mgmt Group LLC 857178 1.79% -1052 -0.12% 2019-03-31
Dimensional Fund Advisors, Inc. 940663 1.96% -71419 -7.06% 2019-03-31
Invesco Ltd (OFI / OppenheimerFunds) 1019589 1.98% -1165363 -53.34% 2019-07-31
Federated Investors Inc 950414 1.98% 8641 0.92% 2019-03-31
Macquarie Investment Management 739178 1.49% -97062 -11.61% 2019-07-31
Amvescap Plc. 2119043 4.41% -196664 -8.49% 2018-12-31
BlackRock Asset Management Canada Ltd 5800597 12.08% -21501 -0.37% 2019-05-31
Geode Capital Management, LLC 907398 1.92% 497885 121.58% 2018-12-31
OFI Global Asset Management, Inc. 938224 2.14% -1185817 -55.83% 2019-04-30
Dimensional Fund Advisors LP 795052 1.81% -2184 -0.27% 2019-03-31
Invesco Advisers, Inc. 731064 1.67% -53093 -6.77% 2019-02-28
TimesSquare Capital Management, LLC 803991 1.83% -1272515 -61.28% 2018-09-30
Ameriprise Financial Inc 895252 2.04% -2139 -0.24% 2018-09-30
William Blair Investment Management, LLC 1363109 3.11% -443195 -24.54% 2018-09-30
Wells Fargo & Co 804762 1.83% -2341 -0.29% 2018-09-30
Invesco Advisers, Inc 1539704 3.51% 267168 20.99% 2018-06-30
BlackRock Institutional Trust Company NA 1126164 2.57% 67203 6.35% 2018-06-30
Delaware Management Business Trust 1107691 2.53% 121157 12.28% 2018-06-30
Ranger Investment Management LP 848989 1.94% 157567 22.79% 2018-06-30
Fidelity Management and Research Company 907513 2.07% -- -- 2018-06-30
Palisade Capital Management LLc 910704 2.08% 148660 19.51% 2018-06-30
Mackenzie Investments 946366 2.16% 6300 0.67% 2018-03-31
FMR Inc 907513 2.07% -- -- 2018-06-30
State Street Corp 1753758 4.00% 154164 9.64% 2018-06-30
Wells Capital Management Inc. 730980 1.67% 68110 10.28% 2018-06-30
Federated Global Inv Mgmt Corp 930956 2.13% 70396 8.18% 2018-03-31
Schroder Investment Management North America Inc. 1284908 9.37% 774950 151.96% 2018-06-30
William Blair Investment Mgmt 556932 1.27% 17500 3.24% 2018-07-31
Columbia Mangmt Investment Advisers, LLC 555941 1.27% 32650 6.24% 2018-03-31
Northern Trust Investments N A 516755 1.18% 4174 0.81% 2018-03-31
Invesco Ltd 1667763 4.93% -326626 -16.38% 2016-12-30
Macquarie Investment Management Limited 752433 1.73% 752433 -- 2017-09-30
Wells Fargo Funds Management LLC 561378 1.29% 70844 14.44% 2017-11-30
Kalmar Investments Inc 661607 1.96% 248929 60.32% 2016-09-30
Renaissance Technologies Corp 1077700 3.19% -47104 -4.19% 2016-09-30
Columbia Wanger Asset Management LLC 559471 1.65% -241406 -30.14% 2016-09-30
BlackRock, Inc. 3361458 3.00% 84271752 0.10% 1999-11-30
Invesco Ltd. 1727787 3.00% 43315620 -- 1999-11-30
FMR LLC 2532805 3.00% 63497421 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
T. Rowe Price QM US Small-Cap Gr Eq Fd 422500 0.82% 12100 2.95% 2019-06-30
Delaware Sm-Cap Core Eq-UBS 739178 1.43% -97062 -11.61% 2019-06-30
iShares Russell 2000 ETF 1041523 2.02% 9003 0.87% 2019-07-30
Vanguard Small Cap Index 1085752 2.11% -14024 -1.28% 2019-06-30
Conestoga Small Cap 1136175 2.20% 24850 2.24% 2019-05-31
Vanguard Total Stock Market Index Fund 1161028 2.25% 229 0.02% 2019-06-30
Hartford MidCap Fund 1322365 2.57% -- -- 2019-06-30
Alger Small Cap Focus Fund 1626412 3.16% 160876 10.98% 2019-05-31
iShares Core S&P Small-Cap ETF 2537385 4.92% 2442 0.10% 2019-07-30
Delaware Small Cap Core Fund 739178 1.43% -94973 -11.39% 2019-06-30
Invesco Oppenheimer Discovery Fund 738863 1.43% 28040 3.94% 2019-06-30
Vanguard Small Cap Growth Index Fund 622784 1.21% -1149 -0.18% 2019-06-30
iShares Russell 2000 Growth ETF 434965 0.84% 5685 1.32% 2019-07-30
SPDR 443207 0.86% 8664 1.99% 2019-07-31
Lord Abbett Developing Growth Fund 486029 0.94% 2707 0.56% 2019-05-31
Ranger Small Cap Tr 529955 1.03% -87605 -14.19% 2019-03-31
Federated Kaufmann Fund 550000 1.07% -- -- 2019-03-31
Vanguard Extended Market Index Fund 576657 1.12% 552 0.10% 2019-06-30
Invesco Small Cap Growth Fund 596109 1.16% -- -- 2019-06-30
iShares S&P Small-Cap 600 Growth ETF 611238 1.19% -- -- 2019-07-30
Vanguard Explorer Fund 412603 0.86% -- -- 2019-03-31
Fidelity 430986 0.90% -73200 -14.52% 2019-04-30
iShares Core MSCI AllCntry Wld exCan ETF 2476851 5.16% -20864 -0.84% 2019-05-23
iShares Core S&P US Total Market ETF 2476413 5.16% -- -- 2019-05-30
iShares US Small Cap ETF (CAD-Hedged) 796696 1.66% -1341 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 1031431 2.18% 3723 0.36% 2019-04-30
Oppenheimer Discovery Fund 651623 1.48% -- -- 2019-03-31
JNL/Invesco Small Cap Growth Fund 406295 0.93% 2441 0.60% 2018-12-31
Invesco S&P SmallCap Health Care ETF 368553 0.84% -- -- 2019-02-27
Oppenheimer International Small-Md Co Fd 1054000 2.40% -156410 -12.92% 2018-11-30
iShares Nasdaq Biotechnology ETF 492345 1.12% -966 -0.20% 2018-11-30
Quadrus Mackenzie US Mid Cap Gr Cl 397155 0.91% -337237 -45.92% 2018-05-31
Mackenzie US Mid Cap Growth Class 397155 0.91% -337237 -45.92% 2018-05-31
iShares Nasdaq Biotechnology 495071 1.17% -942 -0.19% 2018-09-12
JNL/Invesco Small Cap Growth B 401117 0.92% 91620 29.60% 2018-06-30
Vanguard Explorer Inv 412603 0.94% -- -- 2018-06-30
Conestoga Small Cap Investors 1232300 2.81% 29300 2.44% 2018-07-31
Oppenheimer International Small-Mid Co A 1210410 2.76% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 985951 2.25% -- -- 2018-07-31
Delaware Small Cap Core A 869500 1.98% 57700 7.11% 2018-07-31
Ranger Small-Cap Fund 848887 1.94% 157567 22.79% 2018-06-30
iShares S&P Small-Cap 600 Growth 656634 1.56% 8325 1.28% 2018-09-12
Alger Small Cap Focus A 608248 1.39% 109273 21.90% 2018-06-30
Invesco Small Cap Growth A 595168 1.36% 126691 27.04% 2018-06-30
PowerShares S&P SmallCap Health Care ETF 475591 1.14% 9960 2.14% 2018-09-13
Federated Kaufmann R 550000 1.26% -160000 -22.54% 2018-06-30
Vanguard Extended Market Idx Inv 493783 1.13% -- -- 2018-07-31
Oppenheimer Discovery A 450143 1.03% 34410 8.28% 2018-07-31
iShares Russell 2000 Growth 376793 0.89% -363 -0.10% 2018-09-12
William Blair Small-Mid Cap Gr I 440941 1.01% 13600 3.18% 2018-07-31
T. Rowe Price QM US Small-Cap Growth Eq 324700 0.74% 20400 6.70% 2018-06-30
Wells Fargo Emerging Growth Admin 341512 0.78% 34686 11.30% 2018-06-30
AMG TimesSquare Small Cap Growth Instl 320000 0.73% -35000 -9.86% 2018-06-30
Vanguard Tax-Managed Small Cap Adm 316643 0.72% 9300 3.03% 2018-06-30
Pru Ret Small Cap Growth/TimesSquare SP 339000 0.78% -- -- 2018-03-31
Lord Abbett Developing Growth A 471539 1.08% -26770 -5.37% 2017-10-31
DFA US Micro Cap I 327523 0.75% -- -- 2017-10-31
DFA US Small Cap I 240109 0.71% -- -- 2016-12-31
Met Invt Ser Invesco Small Cap Gr A 235032 0.69% -8266 -3.40% 2016-12-31
iShares Core S&P Small-Cap (AU) 852553 2.20% 5740 0.70% 2015-11-18
Oppenheimer International Small Co Fund 839100 2.50% -- -- 2015-09-30
SPDR® S&P Biotech ETF 648741 1.60% 4244 0.70% 2015-11-19
iShares Russell 2000 (AU) 520979 1.40% -327 -0.10% 2015-11-18
RS Small Cap Growth Fund 496400 1.50% -148040 -23.00% 2015-09-30
DFA U.S. Micro Cap Portfolio 375025 1.10% -- -- 2015-09-30
Wells Fargo Advantage Emerging Gr Fund 369250 1.10% -360 -0.10% 2015-09-30
PowerShares Dynamic Biotech&Genome Port 367104 0.90% -- -- 2015-11-19
ASTON/TAMRO Small Cap Fund 363630 1.10% -41851 -10.30% 2015-09-30
Fidelity® Select Biotechnology Portfolio 1861315 5.70% -- -- 2015-09-30

Glenn L. Cooper Currently, Glenn L. Cooper is Chairman of Lascaux Media LLC. Dr. Cooper is also on the board of Repligen Corp. In his past career he held the position of Executive Chairman at Fortress Biotech, Inc., President & Chief Executive Officer of Progenitor, Inc., Chief Operating Officer & Executive Vice President for Sphinx Pharmaceuticals Corp, Chairman & Chief Executive Officer for Indevus Pharmaceuticals, Inc. and Director-Clinical Research at Lilly Research Center Ltd. He received an undergraduate degree from Harvard College and a doctorate from Tufts University School of Medicine.
Karen A. Dawes Karen A. Dawes founded Knowledgeable Decisions LLC. Currently, Ms. Dawes holds the position of Chairman of Repligen Corp. and President of Knowledgeable Decisions LLC. Ms. Dawes is also on the board of Assertio Therapeutics, Inc., Symbiomix Therapeutics LLC, Seaside Therapeutics, Inc. and Medicines 360. Karen A. Dawes previously occupied the position of Chairman of PDL BioPharma, Inc., Vice President-Marketing of Pfizer Inc. Vice President-Commercial Operations at Genetics Institute LLC and Senior Vice President-Global Strategic Marketing at Wyeth Corp. (both are subsidiaries of Pfizer Inc.) and Senior Vice President & Head-US Business Group at Bayer Corp. Karen A. Dawes received a graduate degree and an undergraduate degree from Simmons College (Massachusetts) and an MBA from Harvard University.
Nicolas M. Barthelemy Nicolas M. Barthelemy is on the board of Repligen Corp. and 4 other companies. Mr. Barthelemy previously held the position of Chief Executive Officer & Director at Biotheranostics, Inc., Vice President-Manufacturing at Biogen, Inc., General Manager at Research Triangle Park, Senior Project Engineer-Vaccine Technology at Merck & Co., Inc., President-Cell Systems Division at Invitrogen Corp. and President-Global Commercial Operations at Life Technologies Corp. He received a graduate degree from the University of California, Berkeley and an undergraduate degree from Ecole Sup�0�1�0�8rieure de Physique et de Chimie de Paris.
Karen A. Dawes Karen A. Dawes founded Knowledgeable Decisions LLC. Currently, Ms. Dawes holds the position of Chairman of Repligen Corp. and President of Knowledgeable Decisions LLC. Ms. Dawes is also on the board of Assertio Therapeutics, Inc., Symbiomix Therapeutics LLC, Seaside Therapeutics, Inc. and Medicines 360. Karen A. Dawes previously occupied the position of Chairman of PDL BioPharma, Inc., Vice President-Marketing of Pfizer Inc. Vice President-Commercial Operations at Genetics Institute LLC and Senior Vice President-Global Strategic Marketing at Wyeth Corp. (both are subsidiaries of Pfizer Inc.) and Senior Vice President & Head-US Business Group at Bayer Corp. Karen A. Dawes received a graduate degree and an undergraduate degree from Simmons College (Massachusetts) and an MBA from Harvard University.
Jon K. Snodgres Jon K. Snodgres is Secretary, Chief Financial & Accounting Officer at Repligen Corp. In his past career Mr. Snodgres occupied the position of Vice President-Finance at Thermo Fisher Scientific, Inc. and Chief Financial Officer at MAQUET Cardiovascular LLC. Mr. Snodgres received an undergraduate degree from Northern Arizona University.
Thomas F. Ryan Thomas F. Ryan is on the board of Repligen Corp., Boston College, New York Independent System Operator, Inc. and Mellon Asset Management. In his past career he occupied the position of Chairman for Kidder, Peabody & Co., Inc. and President & Chief Operating Officer for American Stock Exchange LLC. Mr. Ryan received an undergraduate degree from Boston College and an undergraduate degree from Boston Latin School.
Glenn P. Muir Glenn P. Muir is on the board of Repligen Corp., Neuronetics, Inc. and G1 Therapeutics, Inc. and Member of Massachusetts Society of Certified Public Accountants, Inc. and Member of The American Institute of Certified Public Accountants. He previously was Executive Vice President-Finance & Administration at Hologic, Inc., Senior Auditor at Arthur Andersen LLP and Chief Financial Officer & VP-Administration at Metallon Engineered Materials Corp. Glenn P. Muir received an undergraduate degree from the University of Massachusetts, a graduate degree from Bentley University and an MBA from Harvard University.
Sondra S. Newman Presently, Sondra S. Newman is Senior Director-Investor Relations at Repligen Corp. Ms. Newman previously held the position of Director-Investor Relations at NitroMed, Inc.
Stephen Tingley Stephen Tingley holds the position of Vice President-Sales of Repligen Corp. Mr. Tingley received an undergraduate degree from the University of Leeds.
John G. Cox Presently, John G. Cox is Executive Chairman for Torque Therapeutics, Inc. He is also on the board of Repligen Corp. and Sigilon Therapeutics, Inc. Mr. Cox previously occupied the position of EVP-Pharmaceutical Operations & Technology at Biogen, Inc. and Executive Vice President for Biogen Idec New Ventures, Inc. (a subsidiary of Biogen, Inc.), Chief Executive Officer & Director at Bioverativ, Inc., Principal at Covance Biotechnology Services, Inc. and Principal at Wyeth Corp. Mr. Cox received an MBA from the University of Michigan, an undergraduate degree from The California State University and an undergraduate degree from Arizona State University.
Tony J. Hunt Tony J. Hunt is President, Chief Executive Officer & Director at Repligen Corp. In the past Mr. Hunt was President-Bioproduction at Life Technologies Corp. and Senior Director-Pharma Programs at Applied Biosystems, Inc. He received an undergraduate degree and a graduate degree from National University of Ireland and an MBA from Questrom School of Business.
Glenn P. Muir Glenn P. Muir is on the board of Repligen Corp., Neuronetics, Inc. and G1 Therapeutics, Inc. and Member of Massachusetts Society of Certified Public Accountants, Inc. and Member of The American Institute of Certified Public Accountants. He previously was Executive Vice President-Finance & Administration at Hologic, Inc., Senior Auditor at Arthur Andersen LLP and Chief Financial Officer & VP-Administration at Metallon Engineered Materials Corp. Glenn P. Muir received an undergraduate degree from the University of Massachusetts, a graduate degree from Bentley University and an MBA from Harvard University.
Steve Curran Presently, Steve Curran occupies the position of Vice President-Global Operations at Repligen Corp. Mr. Curran received an undergraduate degree from Worcester Polytechnic Institute.
Ralf Kuriyel Currently, Ralf Kuriyel holds the position of Senior Vice President-Research & Development at Repligen Corp. In his past career he held the position of Vice President-Research & Development of Pall Life Sciences and Vice President-Field Applications R&D at Pall Corp. He received an undergraduate degree and a graduate degree from Rensselaer Polytechnic Institute.
Ken Elmer Ken Elmer is Global Head-Human Resources at Repligen Corp. Mr. Elmer previously was Vice President-Human Resources at GlassHouse Technologies, Inc., Chief Human Resources Officer for Attune Consulting USA LLC, Chief People Officer for Viant Corp., Senior Vice President-Human Resources of Celerant Consulting, Inc. and Vice President-Human Resources for Cambridge Technology Partners (Massachusetts), Inc.
Rachel Goodrich Currently, Rachel Goodrich is Vice President-Marketing of Repligen Corp. She received an undergraduate degree from the University of the Philippines and a graduate degree from Stanford University.
Vikas Gupta Vikas Gupta is Vice President-Strategy Growth Initiatives at Repligen Corp. Mr. Gupta received a graduate degree from Bentley University.
Christine Gebski Christine Gebski is VP-Product Cell Culture & Chromatography at Repligen Corp.
Marc J. Centrella Marc J. Centrella is Vice President-Business Development & Strategy at Repligen Corp. In the past Mr. Centrella was Senior Director-Corporate Development & Strategy at Becton, Dickinson & Co. and Director-Corporate Development at Catalent Pharma Solutions, Inc. Mr. Centrella received an undergraduate degree from Ramapo College of New Jersey.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐